The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Depression & Anxiety Linked to Poor Rheumatoid Arthritis Outcomes

Depression & Anxiety Linked to Poor Rheumatoid Arthritis Outcomes

September 18, 2015 • By Rob Goodier

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Rheumatoid arthritis patients with depression and anxiety symptoms may have worse outcomes and poorer response to prednisolone, a secondary analysis of the CARDERA trial has found.

You Might Also Like
  • Anxiety, Depression May Help Predict Outcome of Low Back Pain Treatment
  • Targeted Rheumatoid Arthritis Treatment Does Not Improve Mental Health
  • Experts Discuss Rheumatologists’ Role in Treating Depression, Anxiety and Psychological Comorbidities in Their Patients

“The strength of association between depression/anxiety and disease activity outcomes and treatment response warrants routine screening,” the study’s lead author Faith Matcham at King’s College London in the U.K. told Reuters Health by email.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The analysis, online Sept. 8 in Rheumatology, included 379 of the CARDERA trial’s 467 patients from 42 centers in England and Wales, with two years of follow-up data.

One of the five health domains assessed in the EuroQoL EQ-5DTM questionnaire touches on depression and anxiety symptoms, giving the researchers a measure of severity from baseline through the end of the study.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The researchers compared patients with no depression or anxiety symptoms to those with moderate and severe symptoms, examining their rheumatoid arthritis outcomes according to the DAS28 (disease activity score of 28 joints) and the HAQ (Health Assessment Questionnaire).

After adjusting for variables such as disease duration and baseline HAQ and DAS28 scores, patients with extreme depression and anxiety symptoms at baseline had significantly increased DAS28 scores during follow-up than did those with no baseline depression or anxiety symptoms (standardized mean difference, 0.42).

Baseline depression and anxiety symptoms were linked to a 50% drop in the effect of prednisolone treatment, Matcham and colleagues report.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Differences in HAQ scores were not significant after adjusting for variables, however.

Individuals with depression and anxiety persisting beyond baseline did even more poorly. Compared with patients without such symptoms, they had significantly worse HAQ and DAS28 scores post-treatment even after adjusting for confounders.

“Depression and anxiety are easy and quick to measure and routine screening may identify which subgroups are at risk of much poorer RA outcomes. These patients could be deemed treatment failures on DMARDS, and may end up on biologics at considerable cost. Our data suggests that RA services may get better outcomes if they were able to provide better management for mental disorders and screening is the first crucial step,” Matcham said.

Past research has found nearly more than 16% of rheumatoid arthritis patients screen positive for both depression and anxiety, she and her colleagues note in their report.

Dr. Masayo Kojima from Nagoya City University Graduate School of Medical Sciences in Japan, who was not involved in the research, led a 2009 study on depression, inflammation and pain in rheumatoid arthritis patients, and he echoes the call for mental health screening.

“I believe doctors should check their patients’ mental status routinely. It is necessary at least to have effective communication with their patients,” Dr. Kojima told Reuters Health by email.

Matcham and her colleagues are now studying a more diverse patient population and measuring their depression and anxiety with more rigorous methods, the researcher said.

Pages: 1 2 | Multi-Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: anxiety, Depression, outcome, Rheumatoid Arthritis (RA)

You Might Also Like:
  • Anxiety, Depression May Help Predict Outcome of Low Back Pain Treatment
  • Targeted Rheumatoid Arthritis Treatment Does Not Improve Mental Health
  • Experts Discuss Rheumatologists’ Role in Treating Depression, Anxiety and Psychological Comorbidities in Their Patients
  • Menopause Linked with Functional Decline in Rheumatoid Arthritis

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)